Dapiprazole, an alpha adrenergic blocking drug, as an alternative miotic to pilocarpine or moxisylyte (thymoxamine) for reversing tropicamide mydriasis
DOI :
https://doi.org/10.65636/cjo.v53i4.7159Mots-clés :
dapiprazole, sympatholytiques, miotiques, reflexes pupillairesRésumé
La dapiprazole est un miotique mis au point en Italie et récemment commercialise aux Etats-Unis. Son mécanisme d'action ferait appel au blocage des récepteurs adrénergiques postsynaptiques sur le muscle dilatateur de l’iris. La pharmacocinétique de façon de ce médicament sur la pupille chez I’homme fait l’objet d’un examen, et on discute de son utilisation potentielle pour inverser une dilatation diagnostique de la pupille provoquée par le tropicamide. Son efficacité est comparée à celle de la pilocarpine et un autre inhibiteur adrénergique la moxisylyte (thymoxamine).
Références
1. Krueger PD, Trevino RC. The Canadian Optometry Su1vey: Repo11 on the utilization of diagnostic pharmaceutical agents by Canadi.in opcometris1s. Optom Vision Sci 1990;67:366-71. DOI: https://doi.org/10.1097/00006324-199005000-00012
2. Dough1y MJ, Adamack T, Lyle WM. The use of diagnostic pharmaceutical agents by opcome11is1s in Canada. Report prepared for the Canadian Association of Optometrists. 1988.
3. Spiecker HD. Undtersuchungen zur Strassenverkehstauglichkeit bei medikamentoser Mydriasis und Miosis. Ber Dtsch Ophthalmol Ges 1963;65:353-59.
4. O'Connor PS, Tredici TJ, Pickell, J, Byrne B, Peters OR. Effecrs of routine pupillary dilation on functional daylight vision. Arch Ophthalmol 1988;106:1567-{)9. DOI: https://doi.org/10.1001/archopht.1988.01060140735045
5. Montgomery DMI, Macewan CJ. Pupil dilation with tropicarnide. The effects on acuity, accommodation anti refraction. Eye 1989:3:845-48. DOI: https://doi.org/10.1038/eye.1989.129
6. Rengstorff RH. Doughty CB. Mydriatic and cycloplegic drugs: A review of ocular and systemic complications. Am J Optom Physiol Opt 1982:59:162-77. DOI: https://doi.org/10.1097/00006324-198202000-00008
7. Nelson ME, Orton HP. Counteracting the effects of mydriarics. Does it benefit the patient? Arch Ophthalmol 1987;105:486-89. DOI: https://doi.org/10.1001/archopht.1987.01060040056032
8. Loewenfeld IE. Pupillary changes related to ,1ge. In Thompson HS e<.l., Topics in Neurophthalmology. Baltimore: Williams & Wilkins 1979: 124-50.
9. Buckley C, McA Curlin D, Docherty J. Eustace P. Ageing and alpha1 adrenoceptors in the iris. Eye 1987;1:11-6. DOI: https://doi.org/10.1038/eye.1987.39
10. IJspeen JK. de Waard PJW, van den Berg TJTP. de Jong PTVM. The intraocular straylight function in 129 healthy volunteers: dependence upon angle, age and pigmentation. Vision Res 1990:30:699-707. DOI: https://doi.org/10.1016/0042-6989(90)90096-4
11. Amos JF. Age-related cataract. In Amos JF ed., Diagnosis and Management in Vision Care. Toronto: Butterworths 1987:601-37.
12. Trevino RC. Pupillary dilation in clinical practice. Can J Optom 1988:167-75. DOI: https://doi.org/10.65636/cjo.v50i3.6969
13. Bartlett JD. Dilation of the pupil. In Bartlett JO, Jaanus S eds., Clinical Ocular Pharmacology. Boston: Butterworths. 1989:393-419. DOI: https://doi.org/10.1016/B978-0-7506-9322-6.50025-8
14. Lowe RF. Primary angle-closure glaucoma. investigation using 10% phenylephrine eyedrops. Am J Ophthalmol 1965:60:415-19. DOI: https://doi.org/10.1016/0002-9394(65)90703-8
15. Mapstone R. Mechanics of pupil block. Br J Ophthalmol 1968:52:19-25. DOI: https://doi.org/10.1136/bjo.52.1.19
16. Terry JE. Mydriatic angle-closure glaucoma-mechanism, evaluation and reversal. J Am Optom Assoc 1977:48:159-67.
17. Mapstone R. Safe mydriasis. Br J Ophthalmol 1970:54:690-92. DOI: https://doi.org/10.1136/bjo.54.10.690
18. Wand M, Grant WM. Thymoxamine hydrochloride. Surv Ophthalmol 1980:25:75-84. DOI: https://doi.org/10.1016/0039-6257(80)90150-2
19. Etienne R. La thymoxamine et le glaucome par fermeture de l’angle. J Fr Ophthalmol 1983;6:71-74.
20. Reibaldi A, Cantatore F, Guerriero S. Possibilita della terapia medica nel glaucoma ad angolo chiuso. Boll Oculits 1984;63:669-73.
21. Piccinelli D, Reibaldi A, Sanchez Salorio M (
22. The Merck Index. 11th Edition. Monograph number 2819 (dapiprazole) and 6204 (moxisylyte). Moxisylyte is the generic name approved for use in the USA and Canada; thymoxamine is a European generic name for moxisylyte. Rathway NJ Merck & Co, 1989.
23. Drug Facts and Comparisons. Olin BR. ed., St Louis: Facts & Comparisons Inc. 1991:483a.
24. Hollingworth M. Canadian Divisional Marketing Manager for Storz Pharmaceuticals. Written communication to author (MJD). June 1991.
25. Jaanus SO, Pag:1110 VT, Bartlett JD: Drugs affecting the autonomic nervous system. In Bartlett JD, Jaanus S eds., Clinical Ocular Pharmacology. Boston: Butterworths. 1989:69-148. DOI: https://doi.org/10.1016/B978-0-7506-9322-6.50011-8
26. Havener WH. Ocular Pharmacology. Sr Louis: CV Mosby, 1984.
27. Leopold IH, Potter DE, Duzman E, Novack GO. Pharmacology of ocular catecholamines. In Duane TD, Jaeger EA eds .. Biomedical Foundations of Ophthalmology, vol. 3 (chapter 34). Philadelphia: JB Lippincott, 1988:1-34.
28. McAuliffe-Curtin D, Buckley C. Review of alpha adrenoceptor function in the eye. Eye 1989;3:472-76. DOI: https://doi.org/10.1038/eye.1989.71
29. Loui VJ, LeDeouarec JC, Stone CA. Autonomic nervous system: Adrenergic antagonists. In Sears ML ed., Pharmacology of the Eye. New York: Springer-Verlag, 1984:249-77. DOI: https://doi.org/10.1007/978-3-642-69222-2_6
30. Kern R. Zur medikamentosen Therapie der Glaukome mit Adrenergika und Antiadrenergika. Klin Monatsbl Augenheilkd 1985:186:442-46. DOI: https://doi.org/10.1055/s-2008-1050954
31. Vizi ES. Compounds acting on alpha-1- and alpha-2-adrenoceptors: Agonists and antagonists. Med Res Rev 1986;6:431-49. DOI: https://doi.org/10.1002/med.2610060403
32. MacDonald E. Ruskoaho H, Scheinin M, Virtanen R. Therapeutic applications of drugs acting on alpha-adrenoceptors. Ann Clin Res l988;20:298-310.
33. McGrath JC, Brown CM , Wilson VG. Alpha-adrenoceptors: A critical review. Medicinal Res Reviews l989;9:407-533. DOI: https://doi.org/10.1002/med.2610090403
34. Goodman LS. Gilman A, Rall TW, Nies AS. Taylor P. The Pharmacological Basis of Therapeutics 8th 3d. New York: Pergamon Press, 1990.
35. Borgmann H, Worster W. Der Einfluss unterschiedlieher Konzentrationen und Vehihel auf die Pilocarpine-Miosis I Unterschiedliche knozentrationen. Klin Monatsbl Augenheilkd 1973;163:14-50.
36. Yoshida S. Mishima S. A pharmacokinetic analysis of the pupil response to topical pilocarpine and tropicamide. Jpn J Ophthalmol 1975:19:121-38
37. Iuglio N. Ocular effects of topical application of dapiprazole in man. Glaucoma 1984;6:110-16.
38. Pau H. Sympathikolyse durch locale konjunktivale Opilonapplikation am Auge. Klin Monatsbl Augenheilkd 1955:126:171-76.
39. Turner P, Sneddon JM. Alpha receptor blockade by thymoxamine in the human eye. Clin Pharmacol Therap 1968:9:45-49. DOI: https://doi.org/10.1002/cpt19689145
40. Relf SJ, Gharagozloo NZ, Skuta GL, Alward WLM, Anderson DR, Brubaker RF. Thymoxamine reverses phenylephrine-induced mydriasis. Am J Ophthalmol 1988:106:251-55. DOI: https://doi.org/10.1016/S0002-9394(14)76612-7
41. Diehl DLC, Robin A, Wand M. The influence of iris pigmentation on the miotic effect of thymoxamine. Am J Ophthalmol 1991;111:351-55. DOI: https://doi.org/10.1016/S0002-9394(14)72321-9
42. Lee DA, Rimele TJ, Brubaker RF, Nagataki S. Vanhoutte PM. Effect of thymoxamine on the human pupil. lnvest Ophthalmol Vis Sci 1983;36:655-62. DOI: https://doi.org/10.1016/0014-4835(83)90103-3
43. Correa C. Contribuicao ao estudo de um novo cicloplegico. Rev Bras Oftalmol 1958;17:345-53.
44. Vilmar K-F, Buchmann HH. Uber ein neues Mydriaticum und seine Wirkung auf die Pupillomotorik. Ophthalmologica (Basel) 1958;135:114-22. DOI: https://doi.org/10.1159/000303284
45. Nano HM, Gavarini O, Perez HA. RO 1-7683/15: A new and effective mydriatic. Am J Ophthalmol 1960;2:43-50. DOI: https://doi.org/10.1016/0002-9394(60)91817-1
46. Merrill DL . Goldberg B, Zavell S. bis-Tropicamide, a new parasympatholytic. Curr Ther Res 1960;2:43-50.
47. Miki T. Clinical use of Mydriaticum "Roche" (In Japanese). Acta Soc Ophthalmol Jpn 1961;65:69-74.
48. Mitsui Y, Miki T. A study of a new diagnostic mydriatic (In Japanese). Acta Soc Ophthalmol Jpn 1962:66:174-79.
49. Yamaji R. Huruta I. Sakiyama A. A study of Mydriaticum Roche for pseudomyopia (in Japanese). Acta Soc Ophthalmol Jpn 1963;67:1879-75.
50. Smith SE. Mydriatic drugs for routine fund al inspection. A reappraisal. Lancet 1971:2:837-39. DOI: https://doi.org/10.1016/S0140-6736(71)90218-2
51. Levine L. Effective degree of mydriasis with phenylephrine and tropicamide. Am J Optom Physiol Optics 1976:53:774-85. DOI: https://doi.org/10.1097/00006324-197612000-00004
52. Dillon JR, Tyhurst CW, Yolton RL. The mydriatic effect of 1ropicamide on light and dark irises. J Am Optom Assoc 1977:48:653--58.
53. Pollack SL, Hunt JS. Poise KA. Dose-response effects of tropicamide HCI. Am J Optom Physiol Opt 1981:58:361-66. DOI: https://doi.org/10.1097/00006324-198105000-00003
54. Richardson RW. Comparing the mydriatic effect of tropicamide with respect to iris pigmentation. J Am Optom Assoc 1982:53:885-87.
55. Levine L. Mydriatic effectiveness of dilute combinations of phenylephrine and tropicamide. Am J Optom Physiol Opt 1982;59:580-94. DOI: https://doi.org/10.1097/00006324-198207000-00006
56. Tota G, La Marc F, Gli effeni della tropicamide in rapporto al colore dell'iride. Atti Della Pondazione Giorgio Ranchi 1985:40:177-85.
57. Levine L. Minimizing risk of adverse reactions to mydriatic agents in binocular indirect ophthalmoscopy. J A m Optom Assoc 1985:56:542-48.
58. Mardi JA, Lyle Vivi, Mousa GY. Does prior instillation of a topical anesthetic enhance the effect of tropicamide? Arn J Optom Physiol Opt 1986;63:290-93. DOI: https://doi.org/10.1097/00006324-198604000-00010
59. Steinmann WC. Millstein ME , Sinclair SH. Pupillary dilation with tropicamide 1% for fundoscopic screening. Ann Intern Med 1987;107:181-84, DOI: https://doi.org/10.7326/0003-4819-107-2-181
60. Kergoat H, Lovasik JV, Doughty MJ. A pupillographic evluation of a phenylephrine HC1 5%-tropicamide 0.8% combination mydriatic. J Ocul Pharmacol 1989;5:199-216. DOI: https://doi.org/10.1089/jop.1989.5.199
61. Fleiss JL, Gross AJ. Meta-analysis in epidemiology, with special reference to studies of the association between exposure to environmental tobacco and lung cancer: a critique. J Clin Epidemiol 1991:44: 127-39. DOI: https://doi.org/10.1016/0895-4356(91)90261-7
62. Molinari JF. A clinical comparison of mydriatics. J Am Optom Assoc 1983;54:781-84.
63. Anastasi LM, Ogle KN, Kearns TP. Effect of pilocarpine in counteracting mydriasis. Arch Ophthalmol;79:710-15. DOI: https://doi.org/10.1001/archopht.1968.03850040712009
64. Reeh MJ. Angle-closure glaucoma. Am J Ophthalmol 1958;45:444-46. DOI: https://doi.org/10.1016/0002-9394(58)90831-6
65. Feldman JB. E 3-Lachesine. Am J Ophthalmol 1951;34:442-43. DOI: https://doi.org/10.1016/0002-9394(51)91496-1
66. Barkan O. Narrow-angle glaucoma. Pupillary block and the narrow-angle mechanism. Am J Ophthalmol 1954;37:332-50. DOI: https://doi.org/10.1016/0002-9394(54)91762-6
67. Gorin G. Angle-closure glaucoma induced by miotics. Am J Ophthalmol 1966;62:1063-67. DOI: https://doi.org/10.1016/0002-9394(66)92554-2
68. Rutkowski PC, Thompson HS. Mydriasis and increased intraocular pressure. I Pupillographic studies. Arch Ophthalmol 1972;87:21-24. DOI: https://doi.org/10.1001/archopht.1972.01000020023004
69. Blessel KW, Rudy BC, Senkowski BZ. Tropicamide. ln Florey K ed., Analytical Profiles of Drug Substances, vol. 3. New York: Academic Press 1974:571-80. DOI: https://doi.org/10.1016/S0099-5428(08)60080-5
70. Valeri P, Palmery M, Severini G, Piccinelli D, Catanese B. Ocular pharmacokinetics of dapiprazole. Pharmacol Res Comm 1986:18: 1093-105. DOI: https://doi.org/10.1016/0031-6989(86)90025-1
71. Neufeld AH, Page ED. In vitro determination of the ability of drugs to bind to adrenergic receptors. Invest Ophthalmol Vis Sci 1977;16:1118-24 .•
72. Narita S, Watanabe M. Response of isolated rat iris dilator to adrenergic and cholinergic agents and electrical stimulation. Life Sci 1982;30:1211-18. DOI: https://doi.org/10.1016/0024-3205(82)90665-8
73. Yoshitomi T, ltoh Y, lnomata H. Adrenergic excitatory and cholinergic inhibitory innervations in the human iris dilator. Exp Eye Res 1985;40:453-59. DOI: https://doi.org/10.1016/0014-4835(85)90158-7
74. Shah B, Hubbard B, Stewart-Jones JH, Edgar OF, Turner P. Influence of thymoxamine eye-drops on the mydriatic effect of tropicamide and phenylephrine alone and in combination. Ophthal Physiol Opt 1989;9:153-55. DOI: https://doi.org/10.1111/j.1475-1313.1989.tb00835.x
75. McKinna H, Stewart-Jones JH, Edgar OF, Turner P. Reversal of tropicamide-induced mydriasis by thymoxamine eye drops. Curr Med Res Opinion 1988:11:1-3. DOI: https://doi.org/10.1185/03007998809111123
76. Mapstone R. Acute shallowing of the anterior chamber. Br J Ophthalmol 1981;65:446-51. DOI: https://doi.org/10.1136/bjo.65.7.446
77. Bonomi L, Marchini G, De Feo G, Piccinelli D, Be1tini A. On the reversal of diagnostic mydriasis with dapiprazole. Curr Therap Res 1985;38 945-52.
78. Bonomi L, Tomazzoli L. Thymoxamine and intraocular pressure. Graefes Arch Klin Exptl Ophthalmol 1977;204:95-100. DOI: https://doi.org/10.1007/BF00414710
79. Belluci R, Tovena G, Marraffa M. Utilita’ practica del collirio di dapiprazole nella reversione della midriasi diagnostica. Boll Oculist 1988:67(suppl.3):281-86.
80. Bucci MG, D'Andrea D, Bettini A, De Gregorio M. Dapiprazole for the reversal of mydriasis due to tropicamide. Glaucoma 1987;9:94-98.
81. Mayer GL, Stewart-Jones JH, Turner P. Influence of alpha-receptor blockade with thymoxamine on changes in pupil diameter and accommodation produced by tropicamide and ephedrine. Curr Med Res Opinion 1977:4:660-64. DOI: https://doi.org/10.1185/03007997709115288
82. Pecori Giraldi ]. Taloni M, Bruni P, De Cadilhac C, Giubelei M. Richiamo della midriasi mediante dapaprazolo. Confronto con timoxamina e pilocarpine. Boll Oculist 1988;67(suppl.3):505-8.
83. Nyman N, Keates EU. Effects of dapiprazole on the reversal of pharmacologically induced mydriasis. Optom Vision Sci 1990;67:705-9. DOI: https://doi.org/10.1097/00006324-199009000-00009
Publié-e
Comment citer
Numéro
Rubrique
Licence
Cette œuvre est sous licence Creative Commons Attribution - Pas d'Utilisation Commerciale - Pas de Modification 4.0 International.
